An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

BMC Public Health

Volumn 11, Issue SUPPL. 3, 2011, Pages

  Nair, Harish ^a,b   Verma, Vasundhara R ^a   Theodoratou, Evropi ^a   Zgaga, Lina ^a   Huda, Tanvir ^c   Simões, Eric Af ^d   Wright, Peter F ^e   Rudan, Igor ^a,f   Campbell, Harry ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^c INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^d UNIVERSITY OF COLORADO   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF SPLIT   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ACUTE DISEASE; CHILD; DEVELOPING COUNTRY; ECONOMICS; EVALUATION; HUMAN; IMMUNOLOGY; PASSIVE IMMUNIZATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; VIROLOGY;

ACUTE DISEASE; CHILD; DEVELOPING COUNTRIES; HUMANS; IMMUNIZATION, PASSIVE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS; VACCINES, ATTENUATED;

EID: 79954567948     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-S3-S30     Document Type: Article

References (78)

1. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. H Nair D Nokes B Gessner M Dherani S Madhi R Singleton K O'Brien A Roca P Wright N Bruce A Chandran E Theodoratou A Sutanto E Sedyaningsih M Ngama P Munywoki C Kartasasmita E Simoes I Rudan M Weber H Campbell, Lancet 2010 375 9725 1545 1555 10.1016/S0140-6736(10)60206-1 20399493
2. The Economic Burden of Respiratory Syncytial Virus-Associated Bronchiolitis Hospitalizations. PE Stang, Arch Pediatr Adolesc Med 2001 155 1 95 96 11177073
3. Generic protocol to examine the incidence of lower respiratory infection due to respiratory syncytial virus in children less than 5 years of age. PF Wright FT Cutts, Geneva: World Health Organization 2000 34
4. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. EA Simoes X Carbonell-Estrany CH Rieger I Mitchell L Fredrick JR Groothuis, J Allergy Clin Immunol 2010 126 2 256 262 10.1016/j.jaci.2010.05.026 20624638
5. Sequelae of Severe Respiratory Syncytial Virus Infection in Infancy and Early Childhood Among Alaska Native Children. RJ Singleton GJ Redding TC Lewis P Martinez L Bulkow B Morray H Peters J Gove C Jones D Stamey DF Talkington J DeMain JT Bernert JC Butler, Pediatrics 2003 112 285 290 10.1542/peds.112.2.285 12897275 (Pubitemid 36951387)
6. Severe Respiratory Syncytial Virus Bronchiolitis in Infancy and Asthma and Allergy at Age 13. N Sigurs PM Gustafsson R Bjarnason F Lundberg S Schmidt F Sigurbergsson B Kjellman, Am J Respir Crit Care Med 2005 171 137 141 10.1164/rccm.200406-730OC 15516534 (Pubitemid 40105412)
7. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. RT Stein D Sherrill WJ Morgan CJ Holberg M Halonen LM Taussig AL Wright FD Martinez, Lancet 1999 354 9178 541 545 10.1016/S0140-6736(98)10321- 5 10470697 (Pubitemid 29381367)
8. Setting priorities in global child health research investments: guidelines for implementation of CHNRI method. I Rudan JL Gibson S Ameratunga S El Arifeen ZA Bhutta M Black RE Black KH Brown H Campbell I Carneiro KY Chan D Chandramohan M Chopra S Cousens GL Darmstadt J Gardner Meeks SY Hess AA Hyder L Kapiriri M Kosek CF Lanata MA Lansang J Lawn M Tomlinson AC Tsai J Webster, Croat Med J 2008 49 6 720 733 10.3325/cmj.2008.49.720 19090596
9. The complex challenge of setting priorities in health research investments. I Rudan, Indian J Med Res 2009 129 4 351 353 19535827
10. Setting priorities in global child health research investments: universal challenges and conceptual framework. I Rudan M Chopra L Kapiriri J Gibson M Ann Lansang I Carneiro S Ameratunga AC Tsai KY Chan M Tomlinson SY Hess H Campbell S El Arifeen RE Black, Croat Med J 2008 49 3 307 317 10.3325/cmj.2008.3.307 18581609 (Pubitemid 351955763)
11. Childhood pneumonia and diarrhoea: setting our priorities right. I Rudan S El Arifeen RE Black H Campbell, Lancet Infect Dis 2007 7 1 56 61 10.1016/S1473-3099(06)70687-9 17182344 (Pubitemid 44917782)
12. Setting priorities in global child health research investments: assessment of principles and practice. I Rudan J Gibson L Kapiriri MA Lansang AA Hyder J Lawn GL Darmstadt S Cousens ZA Bhutta KH Brown SY Hess M Black JM Gardner J Webster I Carneiro D Chandramohan M Kosek CF Lanata M Tomlinson M Chopra S Ameratunga H Campbell S El Arifeen RE Black, Croat Med J 2007 48 5 595 604 17948946 (Pubitemid 350022000)
13. Research priorities to reduce global mortality from newborn infections by 2015. R Bahl J Martines N Ali MK Bhan W Carlo KY Chan GL Darmstadt DH Hamer JE Lawn DD McMillan P Mohan V Paul AC Tsai CG Victora MW Weber AK Zaidi I Rudan, Pediatr Infect Dis J 2009 28 1 Suppl 43 48 19106763
14. Setting research priorities to reduce global mortality from childhood diarrhoea by 2015. O Fontaine M Kosek S Bhatnagar C Boschi-Pinto KY Chan C Duggan H Martinez H Ribeiro NC Rollins MA Salam M Santosham JD Snyder AC Tsai B Vargas I Rudan, PLoS Med 2009 6 3 41 10.1371/journal.pmed.1000041 19278292
15. Setting priorities in global child health research investments: addressing values of stakeholders. L Kapiriri M Tomlinson M Chopra S El Arifeen RE Black I Rudan, Croat Med J 2007 48 5 618 627 17948948 (Pubitemid 350022002)
16. Setting priorities in child health research investments for South Africa. M Tomlinson M Chopra D Sanders D Bradshaw M Hendricks D Greenfield RE Black S El Arifeen I Rudan, PLoS Med 2007 4 8 259 10.1371/journal.pmed.0040259 17760497
17. Setting priorities for global mental health research. M Tomlinson I Rudan S Saxena L Swartz AC Tsai V Patel, Bull World Health Organ 2009 87 6 438 446 10.2471/BLT.08.054353 19565122
18. Research priorities for health of people with disabilities: an expert opinion exercise. M Tomlinson L Swartz A Officer KY Chan I Rudan S Saxena, Lancet 2009 374 9704 1857 1862 10.1016/S0140-6736(09)61910-3 19944866
19. Respiratory syncytial virus vaccine development. Y Murata, Clin Lab Med 2009 29 4 725 739 10.1016/j.cll.2009.07.004 19892231
20. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. PL Collins BR Murphy, Proc Am Thorac Soc 2005 2 2 166 173 10.1513/pats.200501-011AW 16113487 (Pubitemid 41233386)
21. Progress in Respiratory Virus Vaccine Development: Pathogenesis and Corelates of Immunity. http://www.medscape.com/viewarticle/558718
22. Influence of maternal antibodies on neonatal immunization against respiratory viruses. JE Crowe, Clin Infect Dis 2001 33 10 1720 1727 10.1086/322971 11595986 (Pubitemid 33044540)
23. Human and bovine respiratory syncytial virus vaccine research and development. G Meyer M Deplanche F Schelcher, Comp Immunol Microbiol Infect Dis 2008 31 2-3 191 225 10.1016/j.cimid.2007.07.008 17720245 (Pubitemid 351324655)
24. Identification of a Recombinant Live Attenuated Respiratory Syncytial Virus Vaccine Candidate That Is Highly Attenuated in Infants. RA Karron PF Wright RB Belshe B Thumar R Casey F Newman FP Polack VB Randolph A Deatly J Hackell W Gruber BR Murphy PL Collins, J Infect Dis 2005 191 7 1093 1104 10.1086/427813 15747245 (Pubitemid 40404368)
25. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. PF Wright RA Karron SA Madhi JJ Treanor JC King A O'Shea MR Ikizler Y Zhu PL Collins C Cutland VB Randolph AM Deatly JG Hackell WC Gruber BR Murphy, J Infect Dis 2006 193 4 573 581 10.1086/499600 16425137 (Pubitemid 43202749)
26. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. PF Wright RA Karron RB Belshe J Thompson JEJ Crowe TG Boyce LL Halburnt GW Reed SS Whitehead EL Anderson AE Wittek R Casey M Eichelberger B Thumar VB Randolph SA Udem RM Chanock BR Murphy, J Infect Dis 2000 182 5 1331 1342 10.1086/315859 11010838
27. Current respiratory syncytial virus prevention strategies in high-risk infants. LE Weisman, Pediatr Int 2002 44 5 475 480 10.1046/j.1442-200X.2002. 01613.x 12225544
28. Prospects for prevention of childhood infections by maternal immunization. CM Healy CJ Baker, Curr Opin Infect Dis 2006 19 3 271 276 10.1097/01.qco.0000224822.65599.5b 16645489 (Pubitemid 43740366)
29. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. LG Stensballe H Ravn K Kristensen K Agerskov T Meakins P Aaby EA Simoes, J Allergy Clin Immunol 2009 123 2 398 403 10.1016/j.jaci.2008.10.043 19101023
30. Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique. A Roca F Abacassamo MP Loscertales L Quinto X Gomez-Olive F Fenwick JC Saiz G Toms PL Alonso, J Med Virol 2002 67 4 616 623 10.1002/jmv.10148 12116014 (Pubitemid 34747687)
31. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. FM Munoz PA Piedra WP Glezen, Vaccine 2003 21 24 3465 3467 10.1016/S0264-410X(03)00352-9 12850361 (Pubitemid 36792104)
32. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. EA Simoes DH Tan A Ohlsson V Sales EE Wang, Vaccine 2001 20 5-6 954 960 10.1016/S0264-410X(01)00388-7 11738763 (Pubitemid 34015839)
33. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. WP Glezen A Paredes JE Allison LH Taber AL Frank, J Pediatr 1981 98 5 708 715 10.1016/S0022-3476(81)80829-3 7229749 (Pubitemid 11070320)
34. State of the art of new vaccines: Research and development. http://www.who.int/vaccine-research/documents/stateoftheart/en/index.html
35. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. JR Groothuis EA Simoes MJ Levin CB Hall CE Long WJ Rodriguez J Arrobio HC Meissner DR Fulton RC Welliver,, et al. N Engl J Med 1993 329 21 1524 1530 10.1056/NEJM199311183292102 8413475 (Pubitemid 23332437)
36. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-rSV Study Group. The IMpact-RSV Study Group, Pediatrics 1998 102 3 Pt 1 531 537
37. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. X Carbonell-Estrany EA Simoes R Dagan CB Hall B Harris M Hultquist EM Connor GA Losonsky, Pediatrics 2010 125 1 35 51 10.1542/peds.2008-1036 20008423
38. Respiratory syncytial virus market. S Storey, Nat Rev Drug Discov 2010 9 1 15 16 10.1038/nrd3075 20043025
39. Clinical experience with respiratory syncytial virus vaccines. PA Piedra, Pediatr Infect Dis J 2003 22 2 Suppl 94 99 12671459
40. Risk of primary infection and reinfection with respiratory syncytial virus. WP Glezen LH Taber AL Frank JA Kasel, Am J Dis Child 1986 140 6 543 546 3706232 (Pubitemid 16120909)
41. Respiratory syncytial virus: back to basics. WP Glezen, J Allergy Clin Immunol 2009 123 2 404 405 10.1016/j.jaci.2008.11.033 19121859
42. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. M Gomez MA Mufson F Dubovsky C Knightly W Zeng G Losonsky, Pediatr Infect Dis J 2009 28 7 655 658 10.1097/INF.0b013e318199c3b1 19483659
43. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. RS Tang RR Spaete MW Thompson M MacPhail JM Guzzetta PC Ryan K Reisinger P Chandler M Hilty RE Walker MM Gomez GA Losonsky, Vaccine 2008 26 50 6373 6382 10.1016/j.vaccine.2008.09.018 18822334
44. Challenges in developing a pediatric RSV vaccine. JH Schickli F Dubovsky RS Tang, Hum Vaccin 2009 5 9 582 591 19556888
45. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection. S Kim JE Jang JR Yu J Chang, Vaccine 2010 28 22 3801 3808 10.1016/j.vaccine.2010.03.032 20362203
46. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. KH Hsu MD Lubeck AR Davis RA Bhat BH Selling BM Bhat S Mizutani BR Murphy PL Collins RM Chanock,, et al. J Infect Dis 1992 166 4 769 775 10.1093/infdis/166. 4.769 1527411
47. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. T Takimoto JL Hurwitz X Zhan S Krishnamurthy C Prouser B Brown C Coleclough K Boyd RA Scroggs A Portner KS Slobod, Viral Immunol 2005 18 2 255 266 10.1089/vim.2005.18.255 16035938 (Pubitemid 41106005)
48. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. T Takimoto JL Hurwitz C Coleclough C Prouser S Krishnamurthy X Zhan K Boyd RA Scroggs B Brown Y Nagai A Portner KS Slobod, J Virol 2004 78 11 6043 6047 10.1128/JVI.78.11. 6043-6047.2004 15141002 (Pubitemid 38661692)
49. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. L Martinez-Sobrido N Gitiban A Fernandez-Sesma J Cros SE Mertz NA Jewell S Hammond E Flano RK Durbin A Garcia-Sastre JE Durbin, J Virol 2006 80 3 1130 1139 10.1128/JVI.80.3.1130-1139.2006 16414990 (Pubitemid 43134070)
50. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. PL Collins RH Purcell WT London LA Lawrence RM Chanock BR Murphy, Vaccine 1990 8 2 164 168 10.1016/0264-410X(90)90141-8 2336876 (Pubitemid 20163773)
51. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. H Mok S Lee TJ Utley BE Shepherd VV Polosukhin ML Collier NL Davis RE Johnston JE Crowe, J Virol 2007 81 24 13710 13722 10.1128/JVI.01351-07 17928349 (Pubitemid 350247864)
52. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus. YH Fu JS He XB Wang XX Zheng Q Wu C Xie M Zhang W Wei Q Tang JD Song JG Qu T Hong, Biochem Biophys Res Commun 2010 395 1 87 92 10.1016/j.bbrc.2010.03.144 20350532
53. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. MR Murawski LW McGinnes RW Finberg EA Kurt-Jones MJ Massare G Smith PM Heaton AE Fraire TG Morrison, J Virol 2009 84 2 1110 1123 10.1128/JVI.01709-09 19889768
54. Maternal immunization and malaria in pregnancy. PE Duffy, Vaccine 2003 21 24 3358 3361 10.1016/S0264-410X(03)00332-3 12850339 (Pubitemid 36798058)
55. Immunoprophylaxis of respiratory syncytial virus: global experience. EA Simoes, Respir Res 2002 3 Suppl 1 26 33 10.1186/rr187 12119055
56. Routine EPI activities. http://www.who.int/countries/eth/areas/ immunization/routine/en/index3.html
57. Respiratory syncytial virus disease burden in the developing world. DJ Nokes, Amsterdam: Elsevier 2007
58. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. PM Danzon A Towse, Int J Health Care Finance Econ 2003 3 3 183 205 10.1023/A:1025384819575 14625999
59. Cost-effectiveness of influenza vaccination of healthy children. H Salo T Kilpi H Sintonen M Linna V Peltola T Heikkinen, Vaccine 2006 24 23 4934 4941 10.1016/j.vaccine.2006.03.057 16678945 (Pubitemid 43782683)
60. Global incidence of severe acute lower respiratory infections due to seasonal influenza in young children: a systematic review and meta-analyses. H Nair H Campbell Edinburgh Flu Study Group, International Conference on Emerging Infectious Diseases: 2010; Atlanta GA American Society for Microbiology 2010
61. Maternal immunisation in developing countries. B Greenwood, Vaccine 2003 21 24 3436 3441 10.1016/S0264-410X(03)00346-3 12850355 (Pubitemid 36792099)
62. Maternal and neonatal tetanus elimination by 2005: strategies for achieving and maintaining elimination. http://www.who.int/vaccinesdocuments/ DocsPDF02/www692.pdf.
63. Respiratory syncytial virus infection in tropical and developing countries. MW Weber EK Mulholland BM Greenwood, Trop Med Int Health 1998 3 4 268 280 10.1046/j.1365-3156.1998.00213.x 9623927 (Pubitemid 28232663)
64. Climatic, temporal, and geographic characteristics of respiratory syncytial virus disease in a tropical island population. SB Omer A Sutanto H Sarwo M Linehan IG Djelantik D Mercer V Moniaga LH Moulton A Widjaya P Muljati BD Gessner M Steinhoff, Epidemiol Infect 2008 136 10 1319 1327 10.1017/S0950268807000015 18177515
65. Palivizumab (product information). GaithersburgMD:MedImmuneInc. 1998
66. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. S Kamal-Bahl J Doshi J Campbell, Arch Pediatr Adolesc Med 2002 156 10 1034 1041 12361451 (Pubitemid 36343482)
67. High Rate of Indigenous Bronchiolitis and Palivuzumab. JS Whitehall S Boilsetty P Whitehall F Francis R Norton SK Patole, J Paediatr Child Health 2001 37 4 416 417 10.1046/j.1440-1754.2001.0720f.x 11547779 (Pubitemid 32772506)
68. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. D Farina S Rodriguez G Bauer L Novali L Bouzas H Gonzalez C Gilli E Laffaire, Pediatr Infect Dis J 2002 21 4 287 291 10.1097/00006454-200204000- 00006 12075758 (Pubitemid 34326865)
69. Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation. P Chan M Abdel-Latif, Acta Paediatr 2003 92 4 481 485 10.1111/j.1651-2227.2003. tb00582.x 12801117 (Pubitemid 37088479)
70. Co-coverage of preventive interventions and implications for child-survival strategies: evidence from national surveys. CG Victora B Fenn J Bryce BR Kirkwood, Lancet 2005 366 9495 1460 1466 10.1016/S0140-6736(05)67599-X 16243091 (Pubitemid 41483812)
71. Mind the gap: equity and trends in coverage of maternal, newborn, and child health services in 54 Countdown countries. JT Boerma J Bryce Y Kinfu H Axelson CG Victora, Lancet 2008 371 9620 1259 1267 10.1016/S0140-6736(08)60560-7 18406860
72. Making health systems more equitable. DR Gwatkin A Bhuiya CG Victora, Lancet 2004 364 9441 1273 1280 10.1016/S0140-6736(04)17145-6 15464189 (Pubitemid 39311349)
73. Achieving universal coverage with health interventions. CG Victora K Hanson J Bryce JP Vaughan, Lancet 2004 364 9444 1541 1548 10.1016/S0140-6736(04) 17279-6 15500901 (Pubitemid 39410422)
74. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. B Jones X Zhan V Mishin KS Slobod S Surman CJ Russell A Portner JL Hurwitz, Vaccine 2009 27 12 1848 1857 10.1016/j.vaccine.2009.01.041 19200447
75. The Jordan Report 20th Anniversary: accelerated development of vaccines 2002. http://www.niaid.nih.gov/topics/Malaria/Documents/jordan20-2002.pdf
76. The Jordan Report: accelerated development of vaccines 2007. http://www.niaid.nih.gov/about/organization/dmid/Documents/jordan2007.pdf
77. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 1997 99 1 93 99 10.1542/peds.99.1.93 8989345
78. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. JR Groothuis EA Simoes MJ Levin CB Hall CE Long WJ Rodriguez J Arrobio HC Meissner DR Fulton RC Welliver,, et al. N Engl J Med 1993 329 21 1524 1530 10.1056/NEJM199311183292102 8413475 (Pubitemid 23332437)